Mucopolysaccharidosis type II

What is Mucopolysaccharidosis type II?

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a rare genetic disorder that affects the body’s ability to break down complex sugar molecules called glycosaminoglycans. This X-linked recessive condition primarily affects males and is caused by mutations in the IDS gene, which produces the enzyme iduronate-2-sulfatase. Without this enzyme, harmful substances accumulate in cells throughout the body, leading to progressive damage to organs and tissues. The condition affects approximately 1 in 100,000 to 170,000 males worldwide.

Key statistics

Prevalence: 1 in 100,000–170,000 males
Inheritance pattern: X-linked recessive
Age of onset: Usually 2-4 years (severe form), 10-15 years (mild form)
Carrier frequency: Approximately 1 in 50,000–85,000 females

Symptoms

Common features: Coarse facial features, joint stiffness, enlarged liver and spleen (hepatosplenomegaly), growth delays, hearing loss, respiratory problems, behavioral changes.

The symptoms of MPS II vary significantly between individuals and typically develop gradually. Early signs often include frequent ear and respiratory infections, runny nose, and noisy breathing. As the condition progresses, children develop characteristic coarse facial features with a prominent forehead, thick lips, and enlarged tongue. Joint stiffness becomes apparent, particularly in the hands, which may develop a claw-like appearance.

Submit Your Paper

Growth delays are common, with affected children often being shorter than their peers. The liver and spleen become enlarged, causing abdominal distension. Unlike other forms of MPS, corneal clouding is notably absent in MPS II. Many children experience hearing loss due to frequent ear infections and structural changes in the ear.

Respiratory problems develop as tissues thicken in the airways, leading to sleep apnea and breathing difficulties. In the severe form of the disease, progressive intellectual disability and behavioral problems may occur, including hyperactivity, aggression, and developmental regression. The mild form typically preserves intelligence but still involves significant physical symptoms.

Causes and risk factors

MPS II is caused by mutations in the IDS gene located on the X chromosome. This gene provides instructions for making the enzyme iduronate-2-sulfatase, which is essential for breaking down glycosaminoglycans (GAGs). When this enzyme is deficient or absent, GAGs accumulate in lysosomes within cells, causing cellular dysfunction and tissue damage.

The primary risk factor is having a family history of the condition. Since MPS II follows an X-linked recessive inheritance pattern, males are primarily affected because they have only one X chromosome. Females can be carriers and typically do not show symptoms, though some may experience mild manifestations. Each son born to a carrier mother has a 50% chance of being affected, while each daughter has a 50% chance of being a carrier.

Advanced maternal age slightly increases the risk of new mutations, though most cases are inherited from carrier mothers. Consanguinity (marriage between relatives) may increase the likelihood of carrier status in some populations.

Prevention

Currently, there is no way to prevent MPS II as it is an inherited genetic condition. However, genetic counseling and testing play crucial roles in family planning decisions. Carrier testing can identify women who carry the gene mutation, allowing for informed reproductive choices.

Prenatal diagnosis is available through chorionic villus sampling or amniocentesis, which can detect the condition during pregnancy. Preimplantation genetic diagnosis (PGD) may be an option for families using in vitro fertilization. Newborn screening programs in some regions can enable early detection and prompt treatment initiation, which may improve long-term outcomes.

Complications

Without treatment, MPS II leads to progressive multi-system deterioration. Cardiac complications include thickened heart valves, enlarged heart, and eventual heart failure. Respiratory complications worsen over time, with airway obstruction, sleep apnea, and reduced lung capacity potentially becoming life-threatening.

Neurological complications in the severe form include progressive intellectual disability, seizures, and behavioral problems. Joint complications lead to severe contractures and mobility limitations. Spinal cord compression may occur due to skeletal abnormalities, potentially causing paralysis. Vision and hearing problems progressively worsen, and dental issues are common due to gum overgrowth and tooth abnormalities.

Diagnosis

Diagnosis of MPS II involves multiple approaches. Initial suspicion often arises from clinical features and family history. Urine tests measuring elevated GAGs (dermatan sulfate and heparan sulfate) provide supportive evidence but are not diagnostic alone.

The definitive diagnosis requires enzyme activity testing, measuring iduronate-2-sulfatase activity in blood cells, cultured skin cells, or dried blood spots. Genetic testing identifies specific mutations in the IDS gene and confirms the diagnosis while enabling family screening.

Additional diagnostic tests include skeletal X-rays showing characteristic bone changes (dysostosis multiplex), echocardiograms to assess heart function, hearing tests, and neurological evaluations. Some healthcare systems employ newborn screening using dried blood spot testing for early detection.

Treatment

The primary treatment for MPS II is enzyme replacement therapy (ERT) with idursulfase, administered weekly through intravenous infusion. This treatment helps reduce GAG accumulation and may slow disease progression, particularly when started early. However, ERT cannot cross the blood-brain barrier, limiting its effectiveness for neurological symptoms.

Supportive care addresses specific symptoms and complications. Respiratory support may include continuous positive airway pressure (CPAP) for sleep apnea or tracheostomy in severe cases. Cardiac monitoring and treatment of heart problems are essential. Physical and occupational therapy help maintain mobility and function.

Hearing aids or cochlear implants may be necessary for hearing loss. Regular dental care is important due to gum overgrowth and tooth problems. Some patients may require surgical interventions for hernias, carpal tunnel syndrome, or spinal cord compression.

Emerging treatments under investigation include substrate reduction therapy, pharmacological chaperone therapy, and gene therapy approaches that may offer improved outcomes in the future.

Prognosis

The prognosis varies significantly between severe and mild forms of MPS II. In the severe form, without treatment, life expectancy is typically 10-20 years, with death often resulting from respiratory or cardiac complications. Early treatment with ERT may extend life expectancy and improve quality of life, though neurological deterioration continues.

The mild form has a better prognosis, with many individuals surviving into adulthood with appropriate treatment. Intelligence is usually preserved, and with proper management, patients can lead relatively independent lives. However, physical limitations and complications still occur and may worsen over time.

Early diagnosis and treatment initiation are crucial for optimal outcomes. Regular monitoring and comprehensive care can help manage complications and maintain function for longer periods.

Quality of life

Living with MPS II requires comprehensive, lifelong management. Families should work with healthcare teams to develop individualized care plans addressing physical, emotional, and educational needs. Regular exercise within physical limitations helps maintain flexibility and strength, while respiratory exercises may help with breathing problems.

Dietary modifications may be necessary to address swallowing difficulties and maintain nutrition. Educational support is crucial, with many children requiring special education services or accommodations. Mental health support helps families cope with the emotional challenges of living with a progressive condition.

Assistive devices such as mobility aids, communication tools, and adaptive equipment can improve independence and participation in daily activities. Creating accessible home environments and maintaining social connections contribute to better quality of life for both patients and families.

Pregnancy and fertility

Males with MPS II rarely father children due to the severity of the condition and shortened lifespan in many cases. Female carriers typically have normal fertility and can have children, though they require genetic counseling to understand inheritance risks.

Pregnant carriers should receive prenatal care from specialists familiar with genetic conditions. Prenatal diagnosis options should be discussed early in pregnancy. Currently approved medications like idursulfase are not typically used during pregnancy due to limited safety data, though this decision requires careful consideration with healthcare providers.

Children

Children with MPS II require specialized pediatric care addressing their complex medical needs. Early intervention services including physical therapy, speech therapy, and occupational therapy are essential for optimal development. Educational planning should begin early, with many children benefiting from individualized education programs (IEPs).

Behavioral challenges in children with the severe form may require specialized approaches and sometimes medication. Families benefit from connecting with other families affected by MPS through patient organizations and support groups. Transition planning for adolescents should address adult care needs and independence skills.

When to see a doctor

Seek immediate medical attention for severe respiratory distress, signs of heart failure (difficulty breathing, swelling), or neurological changes such as loss of developmental milestones or new weakness. Routine monitoring appointments should address growth, hearing, vision, cardiac function, and respiratory status.

Parents should contact healthcare providers for recurrent infections, new joint stiffness, changes in behavior or development, or any concerns about treatment side effects. Regular follow-up with the specialized MPS care team is essential for optimal management.

Regional context

Limited specific data exists regarding MPS II prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. These populations may have unique genetic variants requiring targeted research. Healthcare infrastructure for managing rare diseases varies across the region, with some areas having limited access to enzyme replacement therapy and specialized care. The Global Medical Journal welcomes contributions from regional researchers and clinicians to better understand MPS II prevalence and management challenges in these areas.

Research and clinical trials

Current research focuses on improving treatments for the neurological aspects of MPS II. Gene therapy trials are investigating ways to deliver functional genes to affected cells, including approaches that may cross the blood-brain barrier. Substrate reduction therapies aim to decrease GAG production rather than replacing the missing enzyme.

Intrathecal enzyme replacement therapy delivers treatment directly to the central nervous system and is under investigation. Advanced drug delivery systems and pharmacological chaperones represent additional research avenues. Families can find current clinical trials at ClinicalTrials.gov or through patient organizations.

Stem cell and bone marrow transplant approaches continue to be studied, though these carry significant risks. Biomarker research aims to improve monitoring of disease progression and treatment response.

Frequently asked questions

Is MPS II the same as Hurler syndrome?

No, MPS II (Hunter syndrome) is different from MPS I (Hurler syndrome). Key differences include MPS II being X-linked (affecting mainly males) and typically not causing corneal clouding, while MPS I is autosomal recessive and does cause corneal clouding.

Can females be affected by MPS II?

Rarely, females can be affected due to X-chromosome inactivation patterns or having only one X chromosome (Turner syndrome). Most females are carriers and typically do not show symptoms, though some may have mild manifestations.

How effective is enzyme replacement therapy?

Enzyme replacement therapy can help reduce organ enlargement, improve respiratory function, and may slow disease progression. However, it cannot reverse existing damage or treat neurological symptoms effectively since it doesn’t cross the blood-brain barrier.

What is the difference between severe and mild forms of MPS II?

The severe form involves progressive intellectual disability and typically manifests in early childhood with more rapid progression. The mild form preserves intelligence and has later onset, though significant physical symptoms still occur.

Can MPS II be cured?

Currently, there is no cure for MPS II. Available treatments can slow progression and manage symptoms but cannot completely stop or reverse the condition. Research into gene therapy and other advanced treatments offers hope for better outcomes in the future.

Support and resources

National MPS Society: mpssociety.org
International MPS Network: mpssociety.org/international-mps-network/
Orphanet: orpha.net
National Organization for Rare Disorders (NORD): rarediseases.org
EURORDIS (European Organisation for Rare Diseases): eurordis.org
Global Genes: globalgenes.org

Related conditions

Mucopolysaccharidosis type I
Mucopolysaccharidosis type III
Mucopolysaccharidosis type IV
Mucopolysaccharidosis type VI
Fabry disease

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.